These innovative compounds represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose https://izaakrnak017642.buyoutblog.com/39120454/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide